key: cord-0037289-mmh6503o
authors: Schnierle, Barbara S.; Suezer, Yasemin; Sutter, Gerd
title: Recombinant poxvirus vaccines in biomedical research
date: 2007
journal: Poxviruses
DOI: 10.1007/978-3-7643-7557-7_15
sha: b1c5cad454d9037a12afd8a1589c2d50730722a3
doc_id: 37289
cord_uid: mmh6503o

In biomedical research recombinant poxviruses are investigated as important candidate medicines to derive advanced options for prevention and/or treatment of infectious diseases or cancer. Genetically engineered viruses can readily synthesize biologically active heterologous proteins, serve to determine relevant targets of cell-mediated and humoral immunity, and identify types of immune responses needed for protection against a multitude of different specific diseases. Substantial progress in vaccine development is based on the availability of exceptionally safe but efficient carrier viruses, on increasingly versatile vector technologies and on the feasibility of large scale manufacturing. Moreover, advances in deciphering the molecular pathways regulating poxvirus-host interactions will provide additional means to potently activate innate immune stimulation upon vaccination and to derive vectors with specifically targeted replicative capacity for experimental tumor therapy.

Poxviruses engineered to express foreign genes have been established as extremely valuable tools in modern biotechnology and for vaccine development in medical and veterinary research (for review see [1] ). Compared to currently marketed vaccines, viral vectors appear still as futuristic option in vaccine development. Yet, many of today's health problems where vaccines are believed to become key medicines are likely not to be solved with existing technologies. Adequate biological and clinical safety, large packaging capacity for recombinant DNA, precise virus-specific control of target gene expression, high-level immunogenicity, lack of persistence or genomic integration in the host, and ease of vector and vaccine production are important features supporting the use of recombinant poxviruses as advanced tools for immunization. While making a multivalent poxvirus vector vaccine has been proposed as a particularly desirable medicinal product [2], recombinant poxviruses are primarily investigated as novel vaccines against major human and animal diseases that still lack effective intervention strategies. A major achievement has been the application of vector viruses providing extraordinary levels of safety with regard to protection of the non-target environment and use in possibly immunocompromised target populations [3, 4] (for review see [5, 6] ). The substantial recent progress in conducting clinical research with candidate vaccines against AIDS, tuberculosis, malaria or tumor diseases may serve as an example. Poxviruses engineered as vector vaccines include viruses from multiple genera with the Orthopoxvirus Vaccinia virus (VACV) [7, 8] and Avipoxviruses [9, 10] being the first and most frequently developed for applications in human and veterinary medicine. Other promising candidate vaccines against animal diseases are derived from Parapox- [11, 12] , Suipox-[13], Capripox- [14] , or Leporipoxviruses [15, 16] . In this review, we attempt to provide an update on the state-of-theart in poxvirus vector technologies and to sum up the recent progress in the development of prophylactic and therapeutic recombinant vaccines.

Poxviruses replicate within the cytoplasm of the infected cell and therefore their genome is not transcribed by cellular enzymes. The virus encodes its own transcription and replication machinery and its DNA is not infectious. The currently most frequently practiced strategy to generate recombinant poxviruses employs homologous DNA recombination in infected cells, a relatively frequent event during poxviral replication (0.1%). Recombination is typically directed by a plasmid-based transfer vector, containing the following features: an expression cassette, including a poxvirus-specific promoter, usually followed by a multiple cloning site to allow the insertion of the foreign gene of choice. In addition, selection or screening procedures are quite useful to ease the clonal isolation of recombinant viruses by plaque purification, which requires the additional insertion of selection marker gene expression cassettes. These heterologous DNA sequences are flanked by poxvirus DNA sequences that direct the recombination to a desired locus in a non-essential region of the poxviral genome (Fig. 1) The standard insertion locus for generating recombinant VACV is the thymidine kinase (TK) locus, which allows the selection of recombinant virus by its TK-negative phenotype due to the insertional inactivation of TK in TK-deficient cells [18] . Recently, an improved dominant negative selection procedure has been developed. A recombinant VACV with an inserted E. coli TK/thymidylate kinase (tk/tmk) fusion gene, which converts 3'-azido-2',3'-dideoxythymidine (AZT) into a toxic compound, has been used to construct recombinants. Inactivation of the tk/tmk gene by insertion of the transfer vector conveniently allows selection by AZT without the requirements of using TK-deficient cells [21] .

Alternatively, the transfer vector contains an antibiotic selection marker or a reporter gene allowing the screening due to a change in phenotype such as co-expression of the E. coli -galactosidase [22] and -glucuronidase [23] . Among the co-expressed antibiotics, the E. coli gpt gene encoding the enzyme xanthine guanine phosphoribosyl transferase is frequently used for Staining procedures require additional time of tissue culture, supplementation of agar overlays, and the use of chromogenic substrates and antibiotics. Complementation of a defect in virus production is a faster and more convenient method to obtain recombinant viruses. A first growth selection protocol was initiated using the VACV host range gene K1L to rescue mutant VACV replication in rabbit kidney RK-13 cells [25] . Blasco and colleagues [26, 27] introduced selection for plaque formation through co-insertion of the F13L gene. A VACV mutant and an appropriate complementing cell line enabled growth selection based on the essential D4R gene function [28] . Transient introduction of the K1L gene into the genome of severely growth-restricted modified VACV Ankara (MVA) is used for simple and efficient selection of recombinant MVA, because co-expression of K1L can also complement the defective MVA life cycle in RK-13 cells [29] [30] [31] .

The large size and the covalently closed hairpin ends of the dsDNA poxvirus genome have been major hurdles for direct in vitro cloning of recombinant viruses. In addition, since poxviral DNA is not infectious, isolated poxvirus genomes require a helper poxvirus supplying essential enzymes that are needed to initiate transcription and replication of the recombinant virus. This helper virus should not recombine with the vector virus and not produce infectious progeny in the cells used for the generation of recombinant virus. Avian poxviruses or leporipoxviruses fulfill this requirement for reactivation of recombinant VACV [32, 33] . In one such approach, a unique restriction site was introduced into the VACV genome and the genome was cloned in two halves in lambda phages. Religation of the two halves together with the recombinant gene between them and direct transfection into helper virus-infected cells allowed the generation of recombinant poxviruses without cloning an intermediate DNA construct in E. coli [32, 34, 35] . Moreover, the efficient generation and reactivation of recombinant VACV from cells transfected with cloned DNA also enabled the construction of cDNA libraries [36] .

Another elegant method to engineer poxvirus vectors has been pioneered recently [37] . The entire VACV genome was cloned into a bacterial artificial chromosome (BAC), which can be engineered in E. coli by homologous recombination with bacteriophage lambda-derived enzymes. The modified BAC clones can be used to produce pure recombinant poxvirus in mammalian cells with the initial assistance of a helper virus, but without further requirements for plaque purification.

Animal models for major viral diseases, such as influenza, hepatitis B, or rabies, have served to provide first strong proof-of-principle for protective prophylactic vaccination with recombinant poxvirus vaccines [7, 8, 38, 39] . To prevent these diseases in humans, reasonably good and safe vaccines have been available, which has certainly contributed to a delay in the pharmaceutical development of poxvirus vectors for medical applications. In contrast, multiple poxvirus vector vaccines are already in use in veterinary medicine. Licensed products in Europe include vaccines based on recombinant VACV and recombinant Canarypox virus for prevention of rabies, equine influenza, and feline leukemia. Moreover, there is a steadily increasing interest to derive and test new vector vaccines, making veterinary medicine an important driving force in the development of advanced medicinal products [40] [41] [42] [43] [44] [45] [46] . In medical research and development, most ongoing efforts focus on the study of candidate vector vaccines against human diseases that are more "difficult" to prevent, e.g. those caused by newly emerging or chronic virus infections, or by bacterial infections, parasites or cancer (for overview see Tab. 1).

A safe and effective human immunodeficiency virus (HIV) vaccine is urgently needed to control the worldwide HIV epidemic. However, the development of a vaccine against AIDS represents a substantial scientific challenge related to HIV antigenic variability, the lacking understanding of immune correlates for protection, limitations of available animal models, and the enormous constraints associated with the probable need for multiple large-scale clinical trials in different parts of the world (for review see [47] ). Moreover, the fragile immune system of HIV-infected individuals sets high standards for candidate vaccine safety. Recently, highly attenuated poxviruses have continued to play a major role in the international search for an AIDS vaccine, which also takes advantage of established technologies for vector vaccine production at an industrial scale. For example, safety- However, HIV has an extraordinary genetic diversity and the "Holy Grail" AIDS vaccine would have to cross-protect against different HIV clades. A major scientific challenge is now to find appropriate antigens or epitopes that elicit a cross-protective immune response. For some time, induction of cellular immunity was the primary focus of HIV vaccine development but the generation of broadly neutralizing antibodies is also believed to be indispensable [56] . Concurrently, data from two studies in the macaque model showed that booster vaccinations with oligomeric or native Env proteins enhance Env-binding and virusneutralizing antibody responses primed by recombinant MVA vaccines, and suggest that such antibodies are indeed likely to play a role in vaccineinduced protection [57, 58] . Hepatitis C is another global health problem caused by a chronic virus infection that still lacks a preventive vaccine, and substantial efforts are currently dedicated to preclinical research in animal model systems [59] . The immunogenicity of the first poxvirus vector vaccines based on recombinant Canarypox virus and recombinant MVA have been tested in HLA-transgenic mouse models [60, 61] .

The threatening episode of suddenly emerging coronavirus infections in humans causing severe acute respiratory syndromes impressively demonstrated the suitability of recombinant poxvirus vaccines to quickly evaluate candidate vaccines against a previously unknown pathogen [62, 63] . Thus, in view of the current struggle to tune-up well established but rather too simple vaccine technologies for preparation against the global threat of an influenza pandemic, it is tempting to look into the possible usefulness of poxvirus vectors for development of more potent third generation influenza virus-specific vaccines.

In addition, recombinant poxviruses have proven to be excellent aspirants for vaccine development against other disastrous infectious diseases with global impact such as tuberculosis and malaria (for reviews see [64, 65] ). The incidence of disease caused by Mycobacterium tuberculosis is steadily increasing often on the basis of poverty-impaired health services, widespread HIV infection, or the emergence of resistant M. tuberculosis.

In recent efforts to elicit more potent anti-mycobacterial immunity, MVA vector viruses served to identify new promising target antigens and resulted in the development of the first subunit vaccines entering clinical testing [66] [67] [68] . Similarly, an effective vaccine against malaria is urgently required and a variety of antigens from Plasmodium falciparum has been expressed and tested with recombinant VACV or avipoxviruses. First clinical trials have been initiated using recombinant MVA and fowlpox virus vectors and suggest the usefulness of prime-boost protocols for eliciting enhanced malaria-specific T cell immunity [69, 70] .

In HIV-infected patients therapeutic immunization is considered as a possible means to achieve viral containment without maintenance of antiretroviral treatment. First data from clinical evaluation of recombinant canarypox virus and recombinant MVA vaccines are encouraging, with efficient expansion of vaccine-stimulated HIV antigen-specific CD8 + and/or CD4 + T cell responses and first evidence of improved virus control [71] [72] [73] [74] .

The identification of tumor-associated antigens (TAA), which are displayed by MHC molecules and recognized by specific T cells, showed that vaccination might serve as an effective therapy for a number of malignancies. The particular potential to activate robust cellular MHC class I-and II-restricted CD8 + and CD4 + T cell responses against recombinant antigens make poxvirus vectors attractive as vaccines for immunotherapeutic approaches against cancer. For experimental cancer therapy, virus antigen-associated malignancies seem to be predestined targets for vaccines because these TAA consist of non-self antigens and do not require breaking of immunotolerance. Taylor and co-workers [75] demonstrated the immunogenicity of an Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma vaccine by reactivating EBV-specific CD8 + and CD4 + memory T cells in vitro. There is evidence for the therapeutic efficacy of poxvirus vaccines delivering human papillomavirus (HPV) E2, E6 or E7 antigens against cervical cancer associated with HPV infection in Phase I/II clinical trials [76] [77] [78] [79] [80] .

Several poxvirus vaccine candidates directed against auto-TAA are also in preclinical and clinical development, using carcinoembryonic antigen (CEA) [81, 82] and prostate-specific antigen (PSA) [83] , and a number of melanoma-associated antigens [84, 85] , like gp100, tyrosinase or Melan-A are the furthest developed vaccination strategies and are summarized by Kwak et al. in [86] . Often these strategies are combined with either cytokines like IL-2 [87, 88] , costimulatory molecules such as B7-1 [89] [90] [91] , CTLA-4 blockade [92] or cellular adjuvants like dendritic cells, to enhance immune responses against antigens that are likely tolerogenic self proteins [93, 94] .

One approach in experimental cancer therapy is based on oncolytic viruses (OV) that were selected or engineered to replicate, propagate and spread exclusively in tumor cells, leading to their destruction, while not affecting normal cells. This targeting is possible because OV exploit the cellular defects that permit tumor cell growth. To date several types of OV have been developed and have entered clinical trials. These trials demonstrated an acceptable safety profile of OV, but limited therapeutic efficacy when used as monotherapy. However, improved performance was noted when OV were used in combination with traditional therapies (chemotherapy or radiation) (reviewed in [95] ).

Replicating VACV is being developed as an oncolytic agent (for review see [96, 97] ) because it is able to infect and spread in a large variety of cells and confers an anti-tumor effect by virus-mediated cell death. The first Phase I clinical trial with a VACV recombinant expressing granulocytemacrophage colony-stimulating factor (GM-CSF) applied intratumorally showed that the vector is well tolerated and efficient to a limited extent in the treatment of cutaneous melanoma [98] . VACV variants have been engineered to improve safety by causing inefficient replication in normal cells but retaining high propagation efficiencies in tumor cells [99] . Deletions of the TK and vaccinia growth factor (VGF) genes were shown to decrease VACV virulence [100, 101] . TK/VGF-negative VACV double mutants are further attenuated and showed an enhanced growth capacity in tumor cells [102] . Preferential replication in tumor cells is attributed to the requirement of TTP for DNA synthesis from the nucleotide pool present in highly dividing cells and the activation of the epidermal growth factor receptor (EGFR) signaling pathway, a frequent abnormality in cancer cells. Another attenuation strategy makes use of the ability of cancer cells to evade the induction of apoptosis. The additional deletion of the viral anti-apoptotic genes SPI-1 and SPI-2 from the VACV genome resulted in a recombinant VACV that preferentially replicated in transformed or p53-negative cells and displayed a significant anti-tumor effect in mouse models [103] . A rabbit poxvirus, Myxoma virus (MV), which causes myxomatosis in European rabbits but is nonpathogenic in man, has also been developed as an oncolytic virus candidate. MV encodes proteins that counteract rabbit interferons but are unable to antagonize interferons of other species, including humans. In normal interferon-responsive human cells, MV replication is blocked [104] . However, MV productively infects a variety of human tumor cells, which are non-responsive to interferon [105] . Since the virus does not infect man there is no pre-existing immunity in the human population. This, together with the apparent inherent tropism for human tumor cells suggests the potential for exploiting MV as novel OV platform.

Live poxviral vectors are particularly attractive because they mimic natural infections, while allowing for de novo synthesis of heterologous vaccine antigens. Hereby, poxviral vector vaccination is expected to elicit appro-priate "danger" signals to the immune system resulting in a preferential recognition and presentation of target antigens. Concerns about the safety of poxviruses, including VACV as the former vaccine successfully used to eradicate human smallpox, have been addressed by the application of viruses that are replication defective and avirulent when tested in vivo.

To date multiple types of poxvirus vectors have been developed and have entered clinical trials, particularly in the areas of HIV/AIDS or cancer vaccine development. Many results suggest satisfying safety and efficacy of poxvirus vector vaccines with regard to eliciting specific immune responses to selected target antigens in humans. Nevertheless, the complexity involved in inducing protective immunity against infections with immunodeficiency viruses or in eliciting potent immune responses against tumour-associated self-antigens suggests that the immunogenicity of candidate vaccines may still need a booster to achieve protective vaccination against AIDS, malaria or cancer. Hereby, exciting recent results from basic poxvirus research help to reveal an astonishing versatility of poxviral strategies to counteract the innate host immune response and will lead to the generation of optimized vectors and even better poxvirus vaccines [106] [107] [108] . 

Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

Recombinant poxviruses as mucosal vaccine vectors

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

The rational design of an AIDS vaccine

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells

Global epidemiology of hepatitis C virus infection

Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins

DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region

Recent advances in the development of adenovirus-and poxvirus-vectored tuberculosis vaccines

Progress in DNA-based heterologous prime-boost immunization strategies for malaria

The Apa protein of Mycobacterium tuberculosis stimulates gamma interferonsecreting CD4 + and CD8 + T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine

Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)

Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4 + -and CD8 + -T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine

Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

Clinical studies of human papilloma vaccines in cervical cancer

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

Poxviruses as vectors for cancer immunotherapy

Gene-based vaccines and immunotherapeutics

Technology evaluation: TG-1031

Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules

Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo

Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules

CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model

Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinaseand melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

Recent progress in the battle between oncolytic viruses and tumours

Vaccinia virus and oncolytic virotherapy of cancer

Poxvirus tropism

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

Deletion of the vaccinia virus growth factor gene reduces virus virulence

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2

Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas

Inactivation of the viral interleukin 1beta receptor improves CD8 + T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara

A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA

Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy